tailieunhanh - Case-control Indian buffet process identifies biomarkers of response to Codrituzumab

Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. | Case-control Indian buffet process identifies biomarkers of response to Codrituzumab

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN